not much the company can do. I think they are doing everything they said they would do in terms of the product. its just the market for biotech and anything with a long gestation period such as this is being thrown in the bin.......maybe in time something will come out of it but its surely off to a very bad start at the very least!
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.050(4.85%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 96.0¢ | $192.7K | 195.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 5178 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| EBR (ASX) Chart |